558442-96-9

Upstream product

• 2615-25-0 trans-1,4-cyclohexyldiamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 111-44-4 3-oxa-1,5-dichloropentane 
• 177906-48-8 trans-N-Boc-1,4-cyclohexanediamine 
• 5414-19-7 1,1'-oxybis(2-bromo-ethane) 
• 195314-59-1 tert-butyl (4-aminocyclohexyl)carbamate 

Downstream Products

• 558442-97-0 (1r,4r)-4-(morpholin-4-yl)cyclohexan-1-amine 
• 1447952-43-3 2-(3-[[4-(morpholin-4-yl)cyclohexyl]amino]-8-thia-4,6,12-triazatricyclo[7.4.0.0[2,7]]trideca-1⁽⁹⁾,2⁽⁷⁾,3,5-tetraene-12-sulfonyl)ethan-1-ol 
• 1447952-41-1 12-(ethanesulfonyl)-N-[4-(morpholin-4-yl)cyclohexyl]-8-thia-4,6,12-triazatricyclo[7.4.0.0[2,7]]trideca-1⁽⁹⁾,2⁽⁷⁾,3,5-tetraen-3-amine 
• 1447952-37-5 1-(3-[[4-(morpholin-4-yl)cyclohexyl]amino]-8-thia-4,6,12-triazatricyclo[7.4.0.0[2,7]]trideca-1⁽⁹⁾,2⁽⁷⁾,3,5-tetraen-12-yl)ethan-1-one 
• 1447957-54-1 C₂₂H₃₀N₄O₄S 
• 1447957-55-2 C₂₀H₂₅N₄O₄S^(1-)*Li⁽¹⁺⁾ 
• 1447956-89-9 C₂₇H₃₃N₅O₃S 
• 1447956-90-2 C₁₉H₂₇N₅OS 
• 1447956-84-4 C₂₂H₃₁N₅O₅S₂ 
• 1447953-29-8 4-(((1r,4r)-4-morpholinocyclohexyl)amino)-6,8-dihydro-5H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidine-6-carboxamide 
• 1447952-70-6 [(12S)-3-[[4-(morpholin-4-yl)cyclohexyl]amino]-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1⁽⁹⁾,2,4,6-tetraen-12-yl]methanol 
• 412356-24-2 (1r,4r)-4-(morpholin-4-yl)cyclohexan-1-amine dihydrochloride 

Relevant academic research and scientific papers

TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS

This invention is to methods for treating disorders involving abnormal cellular proliferation that have developed resistance to a selective CDK4/6 inhibitor.

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION

This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY

To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R 1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R 2 is methyl; R 3 is a hydrogen atom; and R 4 is a group: -CONR 5 R 6 (in which any one of R 5 and R 6 is a hydrogen atom)].